Researchers at Dana-Farber Cancer Institute have developed a groundbreaking diagnostic tool that could transform the way acute leukemia is identified and treated. The tool, called MARLIN (Methylation- and AI-guided Rapid Leukemia Subtype Inference), uses DNA methylation patterns and machine learning to classify acute leukemia with speed and accuracy. This tool has the potential to significantly improve patient care by allowing faster and more precise treatment decisions.
Acute leukemia is an aggressive blood cancer that requires accurate diagnosis to guide treatment. Current diagnostic methods, which rely on a combination of molecular and cytogenetic tests, often take days or even weeks to complete. MARLIN, however, can provide results in as little as two hours from the time of biopsy. By providing rapid and detailed insights into leukemia subtypes, MARLIN could enable clinicians to make treatment decisions sooner and with more complete information.

_MoreDetail-v3_x2_1600x1066.jpg)

_MoreDetail-v3_x2_2000x1334.jpg)
.jpg)


_MoreDetail-v3_x2_2560x1440.jpg)






_MoreDetail-v3_x1_2000x1335.jpg)